Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2025 Results presented in the Sanofi media release.
08 Mar 2025 According to a Sanofi media release, the company announced that positive results from this pivotal trial were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
18 Feb 2025 According to a Regeneron Pharmaceuticals and Sanofi media release, if approved , Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com